XLON
HLMA
Market cap19bUSD
Jun 18, Last price
3,958.00GBP
1D
2.17%
1Q
9.40%
Jan 2017
341.00%
Name
Halma PLC
Chart & Performance
P/E
50.44
P/S
6.65
EPS
0.78
Div Yield, %
0.60%
Shrs. gr., 5y
0.01%
Rev. gr., 5y
10.93%
Revenues
2.25b
+10.52%
Net income
296m
+10.27%
CFO
492m
+27.90%
Dividend
Dec 18, 20259.63 GBP/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1894 and based in Amersham, UK, Halma plc is a global group of companies delivering innovative technological products and services across three primary areas: safety, health, and environmental protection. These operations are structured into three distinct segments: Safety, Environmental & Analysis, and Medical. The Safety division focuses on preventing harm and managing risk; its offerings include advanced fire detection and suppression systems, secure elevator operation technologies, various security sensors, solutions for managing human and vehicular traffic, specialized interlocks to ensure safe critical process control, and protective measures against explosions and corrosion. This segment caters to a broad range of industries, such as elevator safety, fire management, access control for industrial settings, secure storage and material transfer, and general people and vehicle movement. Within the Environmental & Analysis segment, Halma develops and supplies technologies for understanding and protecting our surroundings, encompassing sophisticated optical and imaging systems, comprehensive monitoring solutions for water, air, and various gases, devices for identifying dangerous gases and assessing air quality, and advanced systems for water purification and analysis. Key markets for this segment include optical diagnostics, water management, gas sensing, and overall environmental observation. The Medical division is dedicated to supporting healthcare and life sciences; it delivers essential fluidic components for medical diagnostic equipment and OEMs, along with laboratory instruments and systems that generate vital patient health data to guide treatment decisions. This segment also provides technologies and solutions that facilitate in-vitro diagnostics, accelerate life-science research and development, and improve patient outcomes across diverse clinical fields. Its primary markets are life sciences, health evaluation, and therapeutic interventions.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||